BioNTech SE (BNTX)
BNTX Stock Price Chart
Explore BioNTech SE interactive price chart. Choose custom timeframes to analyze BNTX price movements and trends.
BNTX Company Profile
Discover essential business fundamentals and corporate details for BioNTech SE (BNTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Oct 2019
Employees
7.81k
Website
https://www.biontech.deCEO
Ugur Sahin
Description
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
BNTX Financial Timeline
Browse a chronological timeline of BioNTech SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$2.40, while revenue estimate is $183.75m.
Earnings released on 5 May 2026
EPS came in at -$2.43 surpassing the estimated -$2.54 by +4.42%, while revenue for the quarter reached $136.45m , missing expectations by -34.22%.
Earnings released on 10 Mar 2026
EPS came in at -$0.38 falling short of the estimated -$0.22 by -72.73%, while revenue for the quarter reached $1.07bn , beating expectations by +18.11%.
Earnings released on 3 Nov 2025
EPS came in at -$0.14 surpassing the estimated -$1.12 by +87.47%, while revenue for the quarter reached $1.78bn , beating expectations by +110.86%.
Earnings released on 4 Aug 2025
EPS came in at -$1.82 surpassing the estimated -$2.69 by +32.32%, while revenue for the quarter reached $307.08m , beating expectations by +72.71%.
Earnings released on 5 May 2025
EPS came in at -$1.82 surpassing the estimated -$2.48 by +26.55%, while revenue for the quarter reached $200.39m , missing expectations by -6.85%.
Earnings released on 10 Mar 2025
EPS came in at $1.15 surpassing the estimated $0.46 by +148.70%, while revenue for the quarter reached $1.23bn , beating expectations by +4.36%.
Earnings released on 4 Nov 2024
EPS came in at $0.89 surpassing the estimated -$1.74 by +151.11%, while revenue for the quarter reached $1.39bn , beating expectations by +142.92%.
Earnings released on 5 Aug 2024
EPS came in at -$3.62 falling short of the estimated -$2.19 by -65.18%, while revenue for the quarter reached $138.38m , missing expectations by -4.80%.
Earnings released on 6 May 2024
EPS came in at -$1.42 falling short of the estimated -$1.34 by -5.85%, while revenue for the quarter reached $201.53m , missing expectations by -57.97%.
Earnings released on 20 Mar 2024
EPS came in at $2.05 falling short of the estimated $2.62 by -21.76%, while revenue for the quarter reached $1.63bn , missing expectations by -19.78%.
Earnings released on 6 Nov 2023
EPS came in at $0.73 surpassing the estimated -$0.62 by +217.02%, while revenue for the quarter reached $944.40m , beating expectations by +5.04%.
Earnings released on 7 Aug 2023
EPS came in at -$0.86 surpassing the estimated -$0.91 by +5.40%, while revenue for the quarter reached $182.95m , missing expectations by -73.30%.
Earnings released on 8 May 2023
EPS came in at $2.20 surpassing the estimated $0.29 by +665.75%, while revenue for the quarter reached $1.39bn , beating expectations by +20.70%.
Earnings released on 27 Mar 2023
EPS came in at $9.46 surpassing the estimated $8.32 by +13.70%, while revenue for the quarter reached $4.61bn , beating expectations by +17.84%.
Earnings released on 7 Nov 2022
EPS came in at $7.04 surpassing the estimated $3.35 by +110.15%, while revenue for the quarter reached $3.38bn , beating expectations by +67.02%.
Earnings released on 8 Aug 2022
EPS came in at $7.31 falling short of the estimated $7.42 by -1.48%, while revenue for the quarter reached $3.34bn , missing expectations by -17.86%.
Dividend declared on 2 Jun 2022
A dividend of $2.11 per share was announced, adjusted to $2.11. The dividend was paid on 17 Jun 2022.
Earnings released on 9 May 2022
EPS came in at $15.98 surpassing the estimated $10.14 by +57.59%, while revenue for the quarter reached $7.05bn , beating expectations by +46.94%.
Earnings released on 30 Mar 2022
EPS came in at $13.93 surpassing the estimated $8.46 by +64.66%, while revenue for the quarter reached $6.27bn , beating expectations by +40.83%.
Earnings released on 9 Nov 2021
EPS came in at $14.56 surpassing the estimated $11.79 by +23.49%, while revenue for the quarter reached $7.07bn , beating expectations by +24.40%.
Earnings released on 9 Aug 2021
EPS came in at $12.98 surpassing the estimated $8.35 by +55.45%, while revenue for the quarter reached $6.30bn , beating expectations by +93.07%.
BNTX Stock Performance
Access detailed BNTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
